Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine.
The purpose of this study was to investigate the permeability of exendin-4-loaded chitosan nanoparticles using the Madin Darby canine kidney (MDCK) cell monolayer as an in vitro model and the rat intestine as an ex vivo model of the human intestinal barrier. A series of formulations of sodium tripolyphosphate (TPP) and chitosan with different molecular weights and degrees of deacetylation was evaluated. The formulation consisting of 0.1% TPP and 0.2% chitosan (400 kDa, 95% degree of deacetylation), which gave optimized monodispersed particle size (303.1±10.36 nm), zeta potential (18.37±1.15 mV) and encapsulation efficiency (38.0±2.6%), was used for further analysis. After determining their biocompatibility, the transport potential of drug-loaded chitosan nanoparticles was evaluated and compared with free exendin-4 using both MDCK cell monolayers and different rat intestinal segments. Mechanisms underlying enhanced transport of exendin-4 in the cell model were also explored. Compared with free exendin-4, the absorption of optimized chitosan nanoparticles was enhanced by 4.7-fold in MDCK cell monolayers and by 2.0-2.78-fold in different rat intestinal segments, with no significant difference between the duodenum, jejunum and ileum. As supported by confocal laser scanning microscopic analysis, the lower enhancement of absorption in the intestine compared to the cell monolayer likely resulted from the chitosan nanoparticle-mediated opening of cellular tight junctions and not through intracellular transport. These findings suggest that the potential application of chitosan nanoparticles as delivery carriers of exendin-4 is limited and may need further modifications.
National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University.
Mengshu
M
Wang
Yong
Y
Zhang
Bingxue
B
Sun
Yanan
Y
Sun
Xin
X
Gong
Yongge
Y
Wu
Xizhen
X
Zhang
Wei
W
Kong
Yan
Y
Chen
D000818:Animals; D002463:Cell Membrane Permeability / Q000502:physiology*; D002626:Chemistry, Pharmaceutical; D048271:Chitosan / Q000493:pharmacokinetics*; D004285:Dogs; D000077270:Exenatide; D007408:Intestinal Absorption / Q000502:physiology*; D007421:Intestine, Small / Q000166:cytology / Q000378:metabolism*; D061985:Madin Darby Canine Kidney Cells; D023421:Models, Animal; D053758:Nanoparticles / Q000378:metabolism*; D010316:Particle Size; D010455:Peptides / Q000493:pharmacokinetics*; D011122:Polyphosphates / Q000493:pharmacokinetics; D051381:Rats; D013499:Surface Properties; D019108:Tight Junctions / Q000378:metabolism; D014688:Venoms / Q000493:pharmacokinetics*
D010455:Peptides; D011122:Polyphosphates; D014688:Venoms; D048271:Chitosan; D000077270:Exenatide; C005692:triphosphoric acid